Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Investment Securities (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Gains from Investment Securities data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 58737.87% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 12373.04%, while the annual FY2025 figure was $5.3 million, 73.1% down from the prior year.
  • Gains from Investment Securities reached $5.3 million in Q4 2025 per TNGX's latest filing, up from $648749.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $23.8 million in Q1 2025 and bottomed at -$58000.0 in Q1 2021.
  • Average Gains from Investment Securities over 5 years is $2.4 million, with a median of $63000.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: crashed 775.0% in 2024, then skyrocketed 68132.16% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $310000.0 in 2021, then skyrocketed by 136.13% to $732000.0 in 2022, then tumbled by 91.39% to $63000.0 in 2023, then crashed by 114.29% to -$9000.0 in 2024, then skyrocketed by 58737.87% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $5.3 million in Q4 2025, $648749.0 in Q2 2025, and $23.8 million in Q1 2025.